Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-23,600
Closed -$5.76M 3458
2024
Q3
$5.76M Sell
23,600
-12,900
-35% -$2.88M 0.01% 801
2024
Q2
$6.99M Sell
36,500
-7,300
-17% -$1.48M 0.01% 666
2024
Q1
$8.67M Buy
43,800
+29,300
+202% +$5.37M 0.02% 573
2023
Q4
$2.49M Buy
14,500
+7,400
+104% +$1.14M ﹤0.01% 1498
2023
Q3
$1.05M Buy
+7,100
New +$1.28M ﹤0.01% 1973

Other funds holding RMD

GTS Securities's RMD Position: Q2 2026 in Review

GTS Securities increased its ResMed (RMD) stake by 659% in Q2 2026, buying an estimated $1.89M and bringing the position to 10,514 shares worth $2.05M. The position accounts for 0.04% of the portfolio, ranked #248.

GTS Securities first reported a position in RMD in Q4 2023 and has held it in 9 quarters since. The position peaked at $3.84M in Q4 2023. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • GTS Securities held 10,514 shares of ResMed worth $2.05M as of Q2 2026.
  • GTS Securities bought 9,129 ResMed shares in Q2 2026, an estimated $1.89M.
  • ResMed made up 0.04% of GTS Securities's portfolio in Q2 2026, its #248 holding.
  • GTS Securities first reported a position in ResMed in Q4 2023 and has held it in 9 quarters since.
  • GTS Securities's ResMed position peaked at $3.84M in Q4 2023.
  • 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.